tradingkey.logotradingkey.logo
Discount

Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae

PR NewswireNov 16, 2026 1:00 PM
facebooktwitterlinkedin
View all comments(0)

SHANGHAI and SINGAPORE, Nov. 16, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering next-generation outer membrane vesicle (OMV) vaccines, today announced that it has entered into a Research Collaboration Agreement with A*STAR Infectious Diseases Labs (A*STAR IDL), a research institute under Singapore's Agency for Science, Technology and Research (A*STAR).

The collaboration aims to discover and develop novel OMV-based vaccine candidates targeting Klebsiella pneumoniae (K. pneumoniae). By combining Delonix's proprietary pathogenic bacterial genome editing and OMV Plus™ platforms with A*STAR IDL's strong capabilities in translational infectious disease research, clinical relevant bacterial isolates, and immunological evaluation, the collaboration also strengthens Singapore's capabilities to translate infectious disease research towards potential interventions against antimicrobial-resistant pathogens.

K. pneumoniae is a leading cause of life-threatening pneumonia, bloodstream infections, and sepsis, posing severe risks to vulnerable patient populations. The World Health Organization (WHO) has classified carbapenem-resistant Enterobacterales, including K. pneumoniae, as critical-priority pathogens due to high levels of multi-drug resistance against standard clinical therapies [1,2,3].

Despite the significant public health burden, there are currently no licensed vaccines available for K. pneumoniae. Traditional vaccine approaches have been hindered by the pathogen's extensive genetic diversity, thick capsular polysaccharides that mask conserved surface antigens, and high antigenic variation across hypervirulent and multidrug-resistant clinical lineages. Delonix's engineered OMV approach offers a differentiated solution to overcome these barriers. By precisely editing the bacterial genome to modulate capsular interference, detoxify endotoxins, and enrich conserved native antigens on non-replicating vesicles, engineered OMVs has the potential to elicit potent innate and adaptive immune responses capable of broad cross-strain protection.

This partnership marks an important milestone in Delonix's global strategy to build collaborative networks that accelerate the translation of next-generation bacterial vaccines. Driven by a shared commitment to combating antimicrobial resistance (AMR), Delonix and A*STAR IDL will leverage their complementary strengths to generate and evaluate vaccine candidates for safety, immunogenicity, and broad cross-strain protective potential, with the aim of advancing potential preventive approaches against drug-resistant K. pneumoniae.

About Delonix Bioworks

Delonix Bioworks is a clinical-stage biotechnology company at the forefront of developing next-generation genetically engineered bacterial vaccines. Leveraging its proprietary OMV Plus™ platform, the company produces high-yield, cost-effective, and precisely engineered outer membrane vesicles (OMVs) designed for superior antigen presentation and immunogenicity. Delonix is dedicated to advancing a robust pipeline of innovative bacterial vaccine candidates addressing critical unmet needs, including vaccines targeting meningococcal group B (MenB), pertussis, gonorrhoea, and K. pneumoniae infections. Its lead candidate, DX-104, is currently in Phase I clinical trials in Australia and China.

For more information, please visit https://delonixbio.com/.

Business Development & Strategic Partnerships

Email: bd@delonixbio.com

References

[1] WHO. WHO Bacterial Priority Pathogens List, 2024.

[2] WHO. Global Antibiotic Resistance Surveillance Report 2025.

[3] WHO. WHO Warns of Widespread Resistance to Common Antibiotics Worldwide. 2025.

 

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logotradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.